Elutia (NASDAQ:ELUT - Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.01), Zacks reports. The firm had revenue of $5.47 million for the quarter, compared to analyst estimates of $5.90 million.
Elutia Stock Up 2.0 %
Shares of ELUT traded up $0.06 during midday trading on Monday, reaching $2.84. The company had a trading volume of 6,153 shares, compared to its average volume of 38,210. The firm has a 50 day simple moving average of $3.10 and a 200-day simple moving average of $3.64. The stock has a market cap of $97.98 million, a PE ratio of -1.09 and a beta of 0.86. Elutia has a 1-year low of $2.28 and a 1-year high of $5.24.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 target price on shares of Elutia in a research note on Friday.
Read Our Latest Analysis on Elutia
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
Before you consider Elutia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elutia wasn't on the list.
While Elutia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
